Prestige Consumer Healthcare (NYSE:PBH) Q3 2026 Earnings call February 05, 2026 08:30 AM ET Company ParticipantsCarla Casella - Managing DirectorChris Sacco - CFO and COOMitchell Pinheiro - Director of Fundamental Equity ResearchPhil Terpolilli - VP of Investor Relations and TreasuryRon Lombardi - Chairman, President and CEOConference Call ParticipantsJon Anderson - Partner and Research AnalystKeith Davis - Senior Financial AnalystRupesh Parikh - Managing Director and Senior AnalystSusan Anderson - Managing ...

Prestige Consumer Healthcare (NYSE:PBH) Q3 2026 Earnings call February 05, 2026 08:30 AM ET Company ParticipantsCarla Casella - Managing DirectorChris Sacco - CFO and COOMitchell Pinheiro - Director of Fundamental Equity ResearchPhil Terpolilli - VP of Investor Relations and TreasuryRon Lombardi - Chairman, President and CEOConference Call ParticipantsJon Anderson - Partner and Research AnalystKeith Davis - Senior Financial AnalystRupesh Parikh - Managing Director and Senior AnalystSusan Anderson - Managing ...

Prestige Consumer Healthcare (NYSE:PBH) Q3 2026 Earnings call February 05, 2026 08:30 AM ET Speaker1day and thank you for standing by. Welcome to the third quarter, 2026, Prestige Consumer Healthcare Inc. earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your ha ...

Third Quarter FY 26 Results February 5, 2026 Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, adjusted diluted EPS, and free cash flow; the Company's ability to execute on its brand-building strategy to drive organic growth; the Company's ability to maximize shareholder value an ...

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.30%. A quarter ago, it was expected that this medicine distributor would post earnings of $0.97 per share when it actually produced earnings of $1.07, delivering a surprise of +10.31%.Over the last f ...

Last time I covered Premium Brands ( PBH:CA ), I ran the numbers on management’s $10 billion revenue goal for FY 2027 and got to about $110 per share already discounted to present value.I’m an equity analyst and founder of Goulart’s Restaurant Stocks, a research firm focused on the U.S. restaurant industry — from quick-service and fast casual to fine dining and niche concepts. I lead all thematic research and valuation efforts, applying advanced financial modeling, sector-specific KPIs, and strategic insigh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 (State or Other Ju ...

Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results Reported revenues for the first nine months of fiscal 2026 totaled $807.1 million and compared to revenues of $841.2 million for the first nine months of fiscal 2025. Revenues decreased 4.1% versus the prior year comparable period and 3.9% excluding the impact of foreign currency. The revenue performance for the first nine months reflected the limited ability to supply strong demand for Clear Eyes® as w ...

Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial r ...

We came across a bullish thesis on Prestige Consumer Healthcare Inc. on CopyCat Invest’s Substack. In this article, we will summarize the bulls’ thesis on PBH. Prestige Consumer Healthcare Inc.'s share was trading at $63.90 as of January 29th. PBH’s trailing and forward P/E were 15.63 and 13.02 respectively according to Yahoo Finance. Wave Life (WVE) Shares Nearly Triple on Encouraging Obesity Drug Trial Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, d ...